- Home
- GLU vs BOLD Comparison
GLU vs BOLD Comparison
Compare GLU & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | GLU | BOLD |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.8M | 26.9M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | GLU | BOLD |
|---|---|---|
| Price | $19.75 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 12.4K | ★ 129.8K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 8.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.61 | $1.00 |
| 52 Week High | $15.40 | $2.77 |
Technical Indicators
Market Signals| Indicator | GLU | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 67.10 | 53.77 |
| Support Level | $19.43 | $1.14 |
| Resistance Level | $20.21 | $1.35 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 75.55 | 50.00 |
Price Performance
Historical ComparisonAbout GLU Gabelli Global Utility of Beneficial Ownership
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.